No Data
No Data
Piper Sandler Remains a Hold on Supernus Pharmaceuticals (SUPN)
TD Cowen Maintains Supernus Pharmaceuticals(SUPN.US) With Buy Rating, Maintains Target Price $44
Earnings Call Summary | Supernus Pharmaceuticals(SUPN.US) Q1 2025 Earnings Conference
Supernus Projects $600M-$630M Revenue for 2025 With Robust Growth in Core Products
Optimistic Growth Prospects for Supernus Pharmaceuticals Driven by Qelbree's Market Potential
SUPERNUS PHARMACEUTICALS Earnings Results: $SUPN Reports Quarterly Earnings